Park Avenue Securities LLC Buys 1,459 Shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM)

Park Avenue Securities LLC lifted its position in Tandem Diabetes Care, Inc. (NASDAQ:TNDM) by 20.3% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 8,650 shares of the medical device company’s stock after acquiring an additional 1,459 shares during the quarter. Park Avenue Securities LLC’s holdings in Tandem Diabetes Care were worth $306,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in TNDM. RiverPark Advisors LLC bought a new stake in Tandem Diabetes Care in the 4th quarter worth about $27,000. Signaturefd LLC increased its position in shares of Tandem Diabetes Care by 871.8% during the fourth quarter. Signaturefd LLC now owns 1,691 shares of the medical device company’s stock valued at $50,000 after acquiring an additional 1,517 shares during the last quarter. PNC Financial Services Group Inc. lifted its holdings in Tandem Diabetes Care by 51.7% during the third quarter. PNC Financial Services Group Inc. now owns 3,226 shares of the medical device company’s stock worth $67,000 after acquiring an additional 1,099 shares during the period. GAMMA Investing LLC purchased a new position in Tandem Diabetes Care in the fourth quarter worth $73,000. Finally, Creative Financial Designs Inc. ADV bought a new position in Tandem Diabetes Care in the 4th quarter valued at $104,000.

Insider Buying and Selling

In other news, Director Dick Allen sold 5,000 shares of Tandem Diabetes Care stock in a transaction dated Thursday, May 30th. The stock was sold at an average price of $51.68, for a total transaction of $258,400.00. Following the completion of the sale, the director now owns 24,396 shares in the company, valued at approximately $1,260,785.28. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. 2.20% of the stock is owned by company insiders.

Tandem Diabetes Care Trading Down 0.3 %

Shares of Tandem Diabetes Care stock opened at $40.29 on Monday. The company’s 50-day moving average price is $44.52 and its 200-day moving average price is $33.97. The company has a market cap of $2.60 billion, a price-to-earnings ratio of -18.57 and a beta of 1.27. Tandem Diabetes Care, Inc. has a 12-month low of $13.82 and a 12-month high of $53.69. The company has a current ratio of 3.81, a quick ratio of 3.01 and a debt-to-equity ratio of 1.43.

Tandem Diabetes Care (NASDAQ:TNDM) last announced its quarterly earnings results on Thursday, May 2nd. The medical device company reported ($0.63) EPS for the quarter, beating the consensus estimate of ($0.80) by $0.17. The firm had revenue of $191.67 million during the quarter, compared to the consensus estimate of $173.06 million. Tandem Diabetes Care had a negative net margin of 18.37% and a negative return on equity of 34.38%. On average, equities analysts expect that Tandem Diabetes Care, Inc. will post -1.71 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on the company. Oppenheimer lifted their target price on Tandem Diabetes Care from $47.00 to $58.00 and gave the stock an “outperform” rating in a research note on Monday, June 10th. Robert W. Baird boosted their target price on shares of Tandem Diabetes Care from $28.00 to $36.00 and gave the company a “neutral” rating in a research note on Friday, May 3rd. Wells Fargo & Company raised shares of Tandem Diabetes Care from an “equal weight” rating to an “overweight” rating and increased their target price for the company from $21.00 to $45.00 in a research report on Monday, April 29th. SVB Leerink raised shares of Tandem Diabetes Care from a “market perform” rating to an “outperform” rating and lifted their price target for the stock from $34.00 to $45.00 in a report on Thursday, April 25th. Finally, Leerink Partnrs raised Tandem Diabetes Care from a “market perform” rating to an “outperform” rating in a report on Thursday, April 25th. Two analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $51.25.

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.